Kelly McClymont
banner
kmcclymont.bsky.social
Kelly McClymont
@kmcclymont.bsky.social
Histopathologist... Brisbane, Australia. Renal, liver, gastrointestinal dx.
Reposted by Kelly McClymont
6) Immunohistochemistry: PCT is positive in 77% of FLC, but absent in other primary or secondary liver tumors.

In conclusion
👉 serum and tumor PCT = sensitive & specific biomarker for fibrolamellar hepatocellular carcinoma.
November 23, 2025 at 10:59 AM
Reposted by Kelly McClymont
1) We recently identified as serum tumor biomarker of fibrolamellar carcinoma, procalcitonin, with @zucmanrossi.bsky.social and @markyarchoan.bsky.social that you can find in www.medrxiv.org/content/10.1...
Serum Procalcitonin: A Novel Tumor Biomarker for Diagnosis and Follow-Up in Fibrolamellar Hepatocellular Carcinoma
Introduction: Fibrolamellar carcinoma (FLC) is a rare primary liver cancer that predominantly affects young patients with normal known serum tumor biomarkers (alpha-fetoprotein (AFP) and CA19-9). An o...
www.medrxiv.org
November 23, 2025 at 10:59 AM
Reposted by Kelly McClymont
KikoXP + WSI + videoconferencing + 3 subspecialty experts = new way to educate

#pathsky

youtu.be/LVXlir8s8ik?...
Pathology of mesothelioma (featuring biphasic mesothelioma and talc pleurodesis)
YouTube video by Sanjay Mukhopadhyay
youtu.be
November 22, 2025 at 7:19 PM
Reposted by Kelly McClymont
Arteriole with features of a old recanalized thombus in a transplant kidney biopsy. Multiple slit like vascular spaces within the fibrotic lumen. Not a lesion I see often. Pt had clinically diagnosed TMA a few months prior. #renalpath #pathsky #nephsky
November 18, 2025 at 6:29 PM
Reposted by Kelly McClymont
🚀Launching the #LiverRiskScore app!
📱A simple digital tool to spot liver disease risk early using routine clinical data!
🔗iOS: apps.apple.com/us/app/liver...
🔗Android play.google.com/store/apps/d...
@ihieurope.bsky.social @easlnews.bsky.social
‎LiverRisk Score
‎This Liver Risk Score should not be used by the general public. To use this instrument, prior knowledge in biomedicine is necessary. The Liver Risk Score is an easy and simple to use calculator aimed...
apps.apple.com
June 18, 2025 at 6:24 PM
Reposted by Kelly McClymont
Eosinophil rich cellular rejection is often associated with vascular rejection. One of the most eosinophilic txp biopsies I've seen. ACR III (v3 lesion). Undetectable CNI level at admission. #renalpath #nephsky #pathsky
June 7, 2025 at 1:56 PM
Reposted by Kelly McClymont
New platform, same mission.
The CAP is now on Bluesky—join us as we share updates that matter to pathologists and the future of medicine. #pathology #Pathsky
April 9, 2025 at 8:57 PM
Reposted by Kelly McClymont
Research
April 5, 2025 at 7:06 AM
Reposted by Kelly McClymont
What most people think of how a kidneybworks and how the business of nephrology works.
Dr. Gaddy (living kidney donor)
#RPA25 @renalphysicians.bsky.social #organdonation #nephsky
April 4, 2025 at 4:35 PM
Reposted by Kelly McClymont
Interested in learning more about the art of microscopic examination of the urinary sediment and its clinical applications? @jrseltzer.bsky.social @swethakanduri.bsky.social and I will be running a Hands-On Workshop at KidneyCon this year. Come join us! @kidneycon.bsky.social May 1-3. Register ASAP
April 1, 2025 at 6:26 PM
Reposted by Kelly McClymont
One of my favourite tumours morphology-wise, though not to pronounce. I think that’s a statement that only flies on #PathSky 😬
Adamantinomatous craniopharyngioma.
April 1, 2025 at 6:58 AM
Reposted by Kelly McClymont
Delighted to share our recent publication on the state of Pathology Student Interest Groups in U.S. medical schools. Our study highlights current practices and proposes strategies for enhancing student involvement in pathology.

pubmed.ncbi.nlm.nih.gov/40031955/

#Pathology @clilleymd.bsky.social
March 6, 2025 at 1:58 AM
Reposted by Kelly McClymont
The greatest review written on liver biopsy: indications, interpretation, and its future

By Dr Purva Gopal and colleagues in HepCommJournal

Open access journals.lww.com/hepcomm/full...

#liversky #pathsky
January 9, 2025 at 12:46 AM
Reposted by Kelly McClymont
We are on our second starter pack for GI / Hepatology
Part 1: go.bsky.app/8Pho2tp
Part 2: go.bsky.app/VGyLKjR

#medsky #GIsky #LiverSky
November 15, 2024 at 3:17 PM
Reposted by Kelly McClymont
Super little finding. Patient presented with abdominal pain. Here’s a gastric biopsy… #pathsky #pathology #GIPathology #histology #histopathology
January 5, 2025 at 9:18 AM
Reposted by Kelly McClymont
The newly opened Kangaroo Point Bridge (Meanjin) is stunning 😍
December 20, 2024 at 9:26 AM
Reposted by Kelly McClymont
Annals of Surgical Oncology repost:

December Issue: Identification and Verification of Key Genes in #ColorectalCancer #LiverMetastases Through Analysis of Single-Cell Sequencing Data and TCGA Data

rdcu.be/d1TeM
Identification and Verification of Key Genes in Colorectal Cancer Liver Metastases Through Analysis of Single-Cell Sequencing Data and TCGA Data
rdcu.be
December 2, 2024 at 11:04 AM
Reposted by Kelly McClymont
For me, the most incredible artefacts from the ancient world are the letters people wrote on clay tablets and sent to one another over thousands of years in Mesopotamia, going back to more than 5,000 years ago.

They contain recognisable humanity, warmth and humour. Here's a thread of my favourites.
November 17, 2024 at 11:14 AM
Reposted by Kelly McClymont
Thrilled to share our Roadmap to Persister Cancer Cells published in Nature Reviews Cancer. This accomplishment is the result of a collaborative effort by many experts in the field, and I’m proud to represent the RNA community among them
rdcu.be/dSJp4
Cancer drug-tolerant persister cells: from biological questions to clinical opportunities
Nature Reviews Cancer - Resistance to therapy remains the biggest challenge to achieving cures in patients with cancer. In this Roadmap, Russo et al. overview the field of cancer drug-tolerant...
rdcu.be
September 5, 2024 at 5:27 PM
Reposted by Kelly McClymont
"Weird Al" Yankovic - Real or Cake?
youtu.be
April 17, 2024 at 4:19 PM